<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02753426</url>
  </required_header>
  <id_info>
    <org_study_id>15-17569</org_study_id>
    <nct_id>NCT02753426</nct_id>
  </id_info>
  <brief_title>A Trial of Doxycycline in Renal Disease</brief_title>
  <acronym>ADORE</acronym>
  <official_title>A Trial of Doxycycline in Renal Disease (ADORE)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of California, San Francisco</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University of California, San Francisco</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      The goal of this trial is to evaluate whether subantimicrobial-dose of doxycycline (20mgBID)&#xD;
      will affect serum and urine biomarkers of fibrosis in patients with pre-dialysis chronic&#xD;
      kidney disease.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a Phase I, placebo-controlled, randomized crossover trial to determine the effects of&#xD;
      4-week treatment with subantimicrobial-dose doxycycline on serum and urine biomarkers of&#xD;
      fibrosis in patients with pre-dialysis chronic kidney disease (eGFR&lt;30ml/min/1.73m2).&#xD;
      Doxycycline is a matrix metalloproteinase inhibitor and is approved for use as an&#xD;
      anti-fibrotic in the setting of gum and skin disease at low doses (20mgBID). At such a dose,&#xD;
      serum levels are too low for antimicrobial effect and chronic usage is not thought to lead to&#xD;
      tetracycline resistance. Investigators hypothesize that doxycycline will ameliorate cardiac&#xD;
      and renal fibrosis and thus investigators will detect a decrease in fibrotic markers during&#xD;
      treatment with doxycycline.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>April 2016</start_date>
  <completion_date type="Actual">January 2018</completion_date>
  <primary_completion_date type="Actual">December 2017</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Serum markers of fibrosis</measure>
    <time_frame>3 months</time_frame>
    <description>Serum collagen type III amino-terminal propeptide (PIIINP), soluble suppression of tumorigenicity 2 (ST2)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Urinary markers of fibrosis</measure>
    <time_frame>3 months</time_frame>
    <description>Urinary PIIINP, Urinary alpha-1 macroglobulin (A1M)</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Adverse effects</measure>
    <time_frame>3 months</time_frame>
    <description>Nausea, rash</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">11</enrollment>
  <condition>Chronic Kidney Disease</condition>
  <condition>Cardiorenal Syndrome</condition>
  <arm_group>
    <arm_group_label>Doxycycline-Placebo</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>Doxycycline 20mg capsule for 30 days, 30-day washout, and then placebo capsule for 30 days.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo-Doxycycline</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>Placebo capsule for 30 days, 30-day washout, and then Doxycycline 20mg capsule for 30 days.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Doxycycline</intervention_name>
    <description>Doxycycline 20mg capsule by mouth, twice a day for 30 days.</description>
    <arm_group_label>Doxycycline-Placebo</arm_group_label>
    <arm_group_label>Placebo-Doxycycline</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo (for Doxycycline)</intervention_name>
    <description>Inactive pill manufactured to mimic Doxycycline 20mg. Capsule by mouth, twice a for 30 days.</description>
    <arm_group_label>Doxycycline-Placebo</arm_group_label>
    <arm_group_label>Placebo-Doxycycline</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  CKD pre-dialysis (eGFR&lt; 30 ml/min/1.73m2 not on dialysis);&#xD;
&#xD;
          -  local 415/650/510 area codes;&#xD;
&#xD;
          -  primary language English or Spanish&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  eGFR worsening by greater than 5ml/min/1.73 m2 during the last 6 months;&#xD;
&#xD;
          -  Systolic blood pressure less than 100mmHg or greater than 170 mmHg;&#xD;
&#xD;
          -  pregnancy;&#xD;
&#xD;
          -  ejection fraction less than 45%;&#xD;
&#xD;
          -  NYHA class III or IV HF;&#xD;
&#xD;
          -  myocardial infarction or hospitalization for HF within 4 months;&#xD;
&#xD;
          -  liver disease;&#xD;
&#xD;
          -  moderate or severe chronic obstructive pulmonary disease or pulmonary fibrosis;&#xD;
&#xD;
          -  current infection;&#xD;
&#xD;
          -  chemotherapy;&#xD;
&#xD;
          -  major surgery within last month;&#xD;
&#xD;
          -  bilateral dialysis access precluding lab draw;&#xD;
&#xD;
          -  self-reported use of IV drugs or cocaine within the last 6 months.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Ruth Dubin, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of California, San Francisco</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Zuckerberg San Francisco General Hospital</name>
      <address>
        <city>San Francisco</city>
        <state>California</state>
        <zip>94110</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>February 2020</verification_date>
  <study_first_submitted>April 24, 2016</study_first_submitted>
  <study_first_submitted_qc>April 26, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 27, 2016</study_first_posted>
  <last_update_submitted>February 5, 2020</last_update_submitted>
  <last_update_submitted_qc>February 5, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">February 6, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Kidney Diseases</mesh_term>
    <mesh_term>Renal Insufficiency, Chronic</mesh_term>
    <mesh_term>Cardio-Renal Syndrome</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Doxycycline</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

